PAZOPANIB
Generic: PAZOPANIB HYDROCHLORIDE
Novugen Pharma (USA) LLC.Manufacturer
ORALRoute
PAZOPANIB HYDROCHLORIDEActive Substance
2024-04-23Original Approval
PAZOPANIB is FDA application ANDA218231, sponsored by NOVUGEN. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
MALIGNANT NEOPLASM PROGRESSION
532 reports
2
PRODUCT USE IN UNAPPROVED INDICATION
346 reports
3
DIARRHOEA
323 reports
4
DEATH
309 reports
5
DRUG INEFFECTIVE
280 reports
6
FATIGUE
273 reports
7
DISEASE PROGRESSION
261 reports
8
NAUSEA
226 reports
9
OFF LABEL USE
216 reports
10
HYPERTENSION
188 reports